Helix BioPharma (TSE:HBP) Reaches New 52-Week High - Still a Buy?

Key Points

• Helix BioPharma Corp. hit a new 52-week high of C$1.47, representing an 8.9% increase from its previous close of C$1.35 during trading.
• The company has a market cap of C$77.94 million and a price-to-earnings ratio of -1.54, indicating it is currently not profitable.
• Helix BioPharma focuses on cancer drug development and is advancing therapies in immuno-oncology with key pipeline candidates including Tumor Defence Breaker L-DOS47.

Helix BioPharma Corp. (TSE:HBP - ) hit a new 52-week high during trading on Monday . The stock traded as high as C$1.46 and last traded at C$1.47, with a volume of 19350 shares. The stock had previously closed at C$1.35.

Helix BioPharma Stock Up 8.9%

The company has a market cap of C$77.94 million, a price-to-earnings ratio of -1.54 and a beta of -0.84. The company has a 50 day moving average price of C$1.04 and a 200-day moving average price of C$0.94.

About Helix BioPharma

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.